6 results
8-K
EX-99.2
BMY
Bristol-Myers Squibb Co.
2 Feb 24
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
7:46am
therapy ecosystem Industry-leading capabilities in targeted protein degradation Differentiated actinium-based radiopharmaceutical platform1 Expanding
8-K
EX-99.2
BMY
Bristol-Myers Squibb Co.
27 Jul 23
Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
7:50am
Not for Product Promotional Use Guidance Impacted By Change in Outlook for Revlimid and, to a Lesser Extent, Pomalyst 5 Patient Support Ecosystem
8-K
EX-99.2
BMY
Bristol-Myers Squibb Co.
3 Jan 19
Regulation FD Disclosure
7:58am
Biologics and Synthetic Biologics Protein Homeostasis Immunomodulatory Agents Cell Therapies Epigenetics R&D Ecosystem Tumor Biology and Resistance
425
EX-99.2
CELG
Celgene Corporation
3 Jan 19
Business combination disclosure
7:56am
Biologics and Synthetic Biologics Protein Homeostasis Immunomodulatory Agents Cell Therapies Epigenetics R&D Ecosystem Tumor Biology and Resistance
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
8 Jan 24
Regulation FD Disclosure
10:29am
cell therapy ecosystem Industry-leading capabilities in targeted protein degradation Differentiated actinium-based radiopharmaceutical platform1
425
648t9gv
25 Mar 19
Business combination disclosure
5:25pm
- Prev
- 1
- Next